Supernus Pharmaceuticals | SUPN - Operating Expenses


Supernus Pharmaceuticals reported $1.03B in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Abbott USD 11.66B 1.2B Sep/2026
ANI Pharmaceuticals USD 597.21M 34.91M Jun/2026
Aurora Cannabis CAD 48.04M 81.94M Mar/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Canopy Growth CAD 98.72M 11.51M Mar/2026
Cara Therapeutics USD 7.05M 1.11M Mar/2026
Corcept Therapeutics USD 214.85M 343K Jun/2026
Eisai JPY 209.6B 6.14B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Novo Nordisk DKK 44.73B 7.52B Jun/2026
Pacira USD 180.54M 7.79M Jun/2026
Perrigo USD 290.5M 645.1M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Supernus Pharmaceuticals USD 1.03B 45.58M Jun/2026
United Therapeutics USD 6.4B 499.2M Jun/2026
Xeris Pharmaceuticals USD 75.21M 6.18M Mar/2026